AstraZeneca, Merck win quick OK for a rare disease drug — as the FDA declares it can still...

[cafead]

via On Friday, FDA oncology czar Richard Pazdur issued a special press release that noted regulators wasted no time in approving selumetinib from AstraZeneca and Merck, a proven treatment for neurofibromatosis type 1 — NF1 — a genetic disorder that triggers the growth of tumors on children’s nerves.

article source